Abstract 102P
Background
In view of a higher likelihood of risk of having advanced adenoma or invasive cancer in the individual with above average, we investigated whether receiving subsequent faecal immunochemical tests (FITs) in the intervals between colonoscopies could reduce the risk of colorectal cancer (CRC) and advanced colorectal neoplasia (ACN) incidence.
Methods
A retrospective cohort study was performed among high-risk population for CRC between January 2012 and December 2022, in Tianjin, China. The incidence of CRC and ACN were calculated for the FIT surveillance and non-FIT surveillance groups and reported as the number of events per 100000 person-years. Cox proportional hazards model models were applied to evaluate the risks of CRC and ACN, with crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CI).
Results
We included 12515 participants with a high risk of CRC, aged 40-74 years, of whom 4980 received subsequent FIT between colonoscopies during the study period. Among these participants, 51 CRC cases occurred in the non-FIT surveillance group (incidence rate, 233.88 per 100000 person-years) and there were 29 cases of CRC in the FIT surveillance group (incidence rate, 184.85 per 100000 person-years). The cumulative events of the advanced adenoma group were highest, followed by the non-advanced adenoma group, then the no neoplasia group stratified based on the prior colonoscopy findings. Compared with the non-FIT surveillance group, the FIT surveillance group had a 54% decreased risk of developing CRC (HR, 0.46; 95% CI, 0.29-0.74) and a 45% decreased risk of developing ACN (HR, 0.55; 95% CI, 0.47-0.64).
Conclusions
In this CRC surveillance program, our study found that high-risk participants who received subsequent FIT surveillance in the intervals between colonoscopy were associated with a reduction of CRC and ACN incidence, which indicated the value and utility of FIT in the surveillance program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant. No: 81973135 and 81972826) and Science and Technology Commission of Shanghai Municipality (Grant. No: 21XD1402600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract